Please login to the form below
urothelial carcinoma
This page shows the latest urothelial carcinoma news and features for those working in and with pharma, biotech and healthcare.
Tecentriq misses the mark in advanced ovarian cancer
Roche’s drug is approved in a range of cancer types, including urothelial carcinoma, triple-negative cancer and hepatocellular carcinoma.
Latest news
-
Seattle Genetics makes case for Padcev plus Keytruda in first-line bladder cancer
At the tail-end of last year, Seattle and Astellas scored US approval for Padcev (enfortumab vedotin) for the treatment of locally-advanced or metastatic urothelial carcinoma – the most common form ... The initial results from the phase 1b/2 EV-103
-
Keytruda claims first place in bladder cancer race
covers patients with early-stage high grade cancer cells – carcinoma-in-situ (CIS) – with or without papillary tumours. ... Keytruda has already been approved for first- and second-line treatment of urothelial carcinoma, another form of bladder
-
Merck KGaA, Pfizer’s Bavencio improves survival in bladder cancer
In May 2017, Bavencio (avelumab) claimed approval as a second-line treatment in patients with locally advanced or metastatic urothelial carcinoma (UC) whose disease progressed during or following platinum-containing chemotherapy. ... Our unique
-
J&J taps TARIS Biomedical for novel bladder cancer technology
Merck’s blockbuster checkpoint inhibitor Keytruda (pembrolizumab) is also approved for first- and second-line treatment of urothelial carcinoma, the most common form of bladder cancer.
-
Seattle, Astellas bag speedy FDA okay for bladder cancer drug
Padcev (enfortumab vedotin) is indicated for the treatment of locally-advanced or metastatic urothelial carcinoma – the most common form of bladder cancer – in adults who have previously been treated with chemotherapy ... Keytruda has already been
More from news
Approximately 3 fully matching, plus 33 partially matching documents found.
Latest Intelligence
-
Europe vs the US: New drug product approvals
Tecentriq (for the treatment of urothelial carcinoma, only approved in the US), and Venclexta (for the treatment of chronic lymphocytic leukaemia, approved in the EU and US).
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
- New medical communications agency BOLDSCIENCE launches
- Novacyt launches diagnostic test to differentiate between COVID-19 and flu
- 20 for 2020 – Five pharma companies to watch
- FDA approves Roche’s Actemra COVID-19 trial
- Shionogi's Gram-negative antibiotic launches in the UK
- The flexible salesforce
- Navigating engagement and remote working during the pandemic
- Improve clinical trials through patient journey mapping
- Live Webinar: Medical Modeling in Virtual Reality
- Live Webinar: Telemedicine & the Digitization of Medicine post COVID-19
- Havas Health & You Launches Behind the Mask, a Global Research Initiative to Document Health Experiences During the COVID-19 Pandemic and Beyond
PMHub
Research Partnership
We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...
Latest intelligence
- Improve clinical trials through patient journey mapping
- Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
- Alone we can do so little, together we can do so much
- Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
Quick links
Infographics
